A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model.
作者信息
Wu Chuanjian, Wu Manman, Liang Minglong, Xiong Sidong, Dong Chunsheng
机构信息
Jiangsu Key Laboratory of Infection and Immunity, The Institutes of Biology and Medical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou, 215123, Jiangsu, China.
出版信息
Cell Mol Immunol. 2019 Sep;16(9):780-782. doi: 10.1038/s41423-019-0264-7. Epub 2019 Jul 30.
Abstract
摘要
相似文献
1
A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model.一种经PD-L1单链抗体片段改造的新型溶瘤病毒在小鼠模型中有效抑制肿瘤生长。
Cell Mol Immunol. 2019 Sep;16(9):780-782. doi: 10.1038/s41423-019-0264-7. Epub 2019 Jul 30.
2
The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.溶瘤性水疱性口炎病毒（VSV）疗法诱导的针对替代肿瘤抗原的T细胞反应强度与肿瘤控制无关。
Mol Ther. 2014 Jun;22(6):1198-1210. doi: 10.1038/mt.2014.34. Epub 2014 Mar 4.
3
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses.一种表达 PD-L1 抑制剂的工程化溶瘤病毒激活了肿瘤新抗原特异性 T 细胞反应。
Nat Commun. 2020 Mar 13;11(1):1395. doi: 10.1038/s41467-020-15229-5.
4
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.细胞毒性T淋巴细胞相关抗原4（CTLA-4）和程序性死亡受体配体1（PD-L1）检查点阻断增强溶瘤麻疹病毒疗法。
Mol Ther. 2014 Nov;22(11):1949-59. doi: 10.1038/mt.2014.160. Epub 2014 Aug 26.
5
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.肿瘤抗原在溶瘤病毒中的表达增强了抗肿瘤 T 细胞应答。
Nat Commun. 2024 Jun 27;15(1):5442. doi: 10.1038/s41467-024-49286-x.
6
Enhanced Anti-Tumor Response Elicited by a Novel Oncolytic Pseudorabies Virus Engineered with a PD-L1 Inhibitor.新型携带 PD-L1 抑制剂的溶瘤伪狂犬病病毒引发的增强抗肿瘤反应。
Viruses. 2024 Jul 31;16(8):1228. doi: 10.3390/v16081228.
7
Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.联合肿瘤疫苗和溶瘤病毒方法与检查点抑制剂：恶性黑色素瘤的原理、临床前经验和当前临床试验。
Am J Clin Dermatol. 2018 Oct;19(5):657-670. doi: 10.1007/s40257-018-0359-4.
8
Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.细菌介导的肿瘤对溶瘤病毒抗性的敲低增强了治疗效果。
Mol Ther. 2014 Jun;22(6):1188-1197. doi: 10.1038/mt.2014.23. Epub 2014 Feb 26.
9
[Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].新型溶瘤病毒oHSV2hGM-CSF的构建及其抗肿瘤作用
Zhonghua Zhong Liu Za Zhi. 2012 Feb;34(2):89-95. doi: 10.3760/cma.j.issn.0253-3766.2012.02.003.
10
Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models.基于细胞的呼肠孤病毒疫苗在小鼠肺癌和黑色素瘤模型中诱导的抗肿瘤反应。
BMC Cancer. 2016 Jul 13;16:462. doi: 10.1186/s12885-016-2536-2.
引用本文的文献
1
Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities.治疗性结直肠癌疫苗：新兴模式与转化机遇
Vaccines (Basel). 2025 Jun 26;13(7):689. doi: 10.3390/vaccines13070689.
2
Expression of SIRPα-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming.溶瘤病毒介导的信号调节蛋白α-免疫球蛋白Fc段融合蛋白（SIRPα-Fc）表达通过重编程肿瘤微环境增强抗肿瘤疗效。
Front Immunol. 2025 Feb 25;16:1513555. doi: 10.3389/fimmu.2025.1513555. eCollection 2025.
3
Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations.溶瘤性水疱性口炎病毒在癌症病毒治疗中的应用：耐药性及临床考量
Viruses. 2024 Dec 25;17(1):16. doi: 10.3390/v17010016.
4
N6-methyladenosine RNA modification promotes Severe Fever with Thrombocytopenia Syndrome Virus infection.N6-甲基腺嘌呤RNA修饰促进严重发热伴血小板减少综合征病毒感染。
PLoS Pathog. 2024 Nov 25;20(11):e1012725. doi: 10.1371/journal.ppat.1012725. eCollection 2024 Nov.
5
A novel vesicular stomatitis virus armed with IL-2 mimic for oncolytic therapy.一种新型水疱性口炎病毒，携带 IL-2 模拟物用于肿瘤溶瘤治疗。
Virol Sin. 2024 Oct;39(5):821-832. doi: 10.1016/j.virs.2024.09.007. Epub 2024 Sep 17.
6
Oncolytic Viruses in the Era of Omics, Computational Technologies, and Modeling: Thesis, Antithesis, and Synthesis.肿瘤溶瘤病毒在组学、计算技术和建模时代：正题、反题和综合。
Int J Mol Sci. 2023 Dec 12;24(24):17378. doi: 10.3390/ijms242417378.
7
Oncolytic Viruses and Immune Checkpoint Inhibitors: The "Hot" New Power Couple.溶瘤病毒与免疫检查点抑制剂：新兴的“热门”强力组合。
Cancers (Basel). 2023 Aug 19;15(16):4178. doi: 10.3390/cancers15164178.
8
Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy.工程化肿瘤特异性基因纳米药物以招募和激活 T 细胞，增强免疫治疗。
Nat Commun. 2023 Apr 8;14(1):1993. doi: 10.1038/s41467-023-37656-w.
9
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.免疫病毒疗法：抗体药物与溶瘤病毒联合治疗的作用。
Front Immunol. 2022 Oct 13;13:1012806. doi: 10.3389/fimmu.2022.1012806. eCollection 2022.
10
Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival.PD-L1 单链抗体的系统检查点阻断赋予强大的抗肿瘤免疫和长期生存。
Mol Cancer Ther. 2022 Nov 3;21(11):1710-1721. doi: 10.1158/1535-7163.MCT-22-0010.
本文引用的文献
1
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.帕比司他联合γ干扰素使骨髓瘤细胞中PD-L1上调。
Oncotarget. 2019 Mar 8;10(20):1903-1917. doi: 10.18632/oncotarget.26726.
2
The altered PD-1/PD-L1 pathway delivers the 'one-two punch' effects to promote the Treg/Th17 imbalance in pre-eclampsia.PD-1/PD-L1 通路的改变会产生“双重打击”效应，促进子痫前期中 Treg/Th17 的失衡。
Cell Mol Immunol. 2018 Jul;15(7):710-723. doi: 10.1038/cmi.2017.70. Epub 2017 Sep 11.
3
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.溶瘤病毒疗法可促进肿瘤内T细胞浸润并改善抗PD-1免疫疗法。
Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.
4
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.抗程序性死亡配体1（PD-L1）单克隆抗体阿维鲁单抗用于肿瘤治疗的结构基础
Cell Res. 2017 Jan;27(1):151-153. doi: 10.1038/cr.2016.102. Epub 2016 Aug 30.
5
Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library.从靶向表位的哺乳动物细胞展示抗体文库中筛选和鉴定新型抗人 PD-1 FV78 抗体。
Cell Mol Immunol. 2018 Feb;15(2):146-157. doi: 10.1038/cmi.2016.38. Epub 2016 Aug 8.
6
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.嵌合抗原受体T细胞在复发难治性慢性淋巴细胞白血病中持续存在并诱导持续缓解。
Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.
7
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.人类癌症的抗PD-1/PD-L1疗法：过去、现在与未来。
J Clin Invest. 2015 Sep;125(9):3384-91. doi: 10.1172/JCI80011. Epub 2015 Sep 1.
8
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.替莫唑胺胶丸联合放疗治疗恶性脑胶质瘤的疗效观察
J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.
9
Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin.调节对表达鞭毛蛋白的水疱性口炎病毒载体的反应的小鼠树突状细胞中的信号通路。
J Virol. 2014 Jan;88(2):777-85. doi: 10.1128/JVI.02898-13. Epub 2013 Nov 6.
10
Programmed contraction of CD8(+) T cells after infection.感染后CD8(+) T细胞的程序性收缩
Nat Immunol. 2002 Jul;3(7):619-26. doi: 10.1038/ni804. Epub 2002 Jun 3.
Zotero 插件